+ All Categories
Home > Documents > Weng TC, et al. J Clin Pharm Ther 2010;35:139-51.

Weng TC, et al. J Clin Pharm Ther 2010;35:139-51.

Date post: 23-Dec-2015
Category:
Upload: antony-mclaughlin
View: 237 times
Download: 1 times
Share this document with a friend
Popular Tags:
10
Weng TC, et al. J Clin Pharm Ther 2010;35:139- 51
Transcript
Page 1: Weng TC, et al. J Clin Pharm Ther 2010;35:139-51.

Weng TC, et al. J Clin Pharm Ther 2010;35:139-51

Page 2: Weng TC, et al. J Clin Pharm Ther 2010;35:139-51.

Baseline characteristics of statin studies with paired-comparisons

Weng TC, et al. J Clin Pharm Ther 2010;35:139-51

Page 3: Weng TC, et al. J Clin Pharm Ther 2010;35:139-51.

Comparisons of the lipid lowering effect of different statins: LDL

Weng TC, et al. J Clin Pharm Ther 2010;35:139-51

Page 4: Weng TC, et al. J Clin Pharm Ther 2010;35:139-51.

Comparisons of the lipid lowering effect of different statins: HDL

Weng TC, et al. J Clin Pharm Ther 2010;35:139-51

Page 5: Weng TC, et al. J Clin Pharm Ther 2010;35:139-51.

Comparisons of the lipid lowering effect of different statins: TG

Weng TC, et al. J Clin Pharm Ther 2010;35:139-51

Page 6: Weng TC, et al. J Clin Pharm Ther 2010;35:139-51.

Low density lipoprotein (LDL) reduction (%) of different statins in different doses

Weng TC, et al. J Clin Pharm Ther 2010;35:139-51

Page 7: Weng TC, et al. J Clin Pharm Ther 2010;35:139-51.

Weighted mean difference (WMD) with 95% confidence interval (CI) of different statins at equivalent dose

Weng TC, et al. J Clin Pharm Ther 2010;35:139-51

Page 8: Weng TC, et al. J Clin Pharm Ther 2010;35:139-51.

Effects on cardiovascular events

Weng TC, et al. J Clin Pharm Ther 2010;35:139-51

Page 9: Weng TC, et al. J Clin Pharm Ther 2010;35:139-51.

Incidence of specific adverse effects (%)

Weng TC, et al. J Clin Pharm Ther 2010;35:139-51

Page 10: Weng TC, et al. J Clin Pharm Ther 2010;35:139-51.

Flow chart of the article selection

Weng TC, et al. J Clin Pharm Ther 2010;35:139-51


Recommended